Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
August 2021
-
Media ReleaseNovartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphomaPhase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12…
-
Media ReleaseNovartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasisChina National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
-
Media ReleaseNovartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeksResults from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
-
Key ReleaseNovartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMAAd hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
July 2021
-
Key ReleaseNovartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Media ReleaseNovartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equityNovartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
-
Media ReleaseNovartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHDREACH3 data show Jakavi significantly improved overall response rate (ORR) at week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy, among…
June 2021
-
Key ReleaseNovartis appoints Rob Kowalski as Chief People & Organization OfficerBasel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer.…
-
Media ReleaseSandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancerPemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1 New ready-to-dilute format and 1,000 mg strength…
-
Media ReleasePositive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of MedicineVISION manuscript shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved overall survival and radiographic progression-free survival for patients with metastatic castration-…
-
Media ReleaseNovartis and Hewlett Packard Enterprise join forces to advance Novartis global health effortsNovartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and…
-
Media ReleaseKesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosisNew ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1…
Pagination
- ‹ Previous page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- …
- 88
- › Next page